Do ASARM peptides play a role in nephrogenic systemic fibrosis?

American Journal of Physiology - Renal Physiology

Volumn 309, Issue 9, 2015, Pages F764-F769

  Rowe, Peter S N ^a   Zelenchuk, Lesya V ^a   Laurence, Jennifer S ^b   Lee, Phil ^a,c   Brooks, William M ^a,c   McCarthy, Ellen T ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; DMP1; FGF23; MEPE; Nephrogenic system fibrosis; Osteopontin; PHEX; Sclerostin

Indexed keywords

ACIDIC SERINE ASPARTATE RICH MEPE PEPTIDE; CALCIUM ION; CONTRAST MEDIUM; GADOLINIUM; PEPTIDE; UNCLASSIFIED DRUG; GADOBENIC ACID; GADODIAMIDE; GADOLINIUM PENTETATE; GLYCOPROTEIN; MEGLUMINE; MEPE PROTEIN, MOUSE; ORGANOMETALLIC COMPOUND; PEPTIDE FRAGMENT; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHOPROTEIN; PROTEIN BINDING; SCLEROPROTEIN;

ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RISK; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL PROTECTION; CHEMICALLY INDUCED; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG STABILITY; FAMILIAL HYPOPHOSPHATEMIC RICKETS; GENETICS; KIDNEY; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; NEPHROGENIC FIBROSING DERMOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

ANIMALS; CONTRAST MEDIA; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DRUG STABILITY; EXTRACELLULAR MATRIX PROTEINS; FAMILIAL HYPOPHOSPHATEMIC RICKETS; GADOLINIUM DTPA; GLYCOPROTEINS; KIDNEY; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MICE, INBRED C57BL; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; PEPTIDE FRAGMENTS; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SIGNAL TRANSDUCTION; X-RAY MICROTOMOGRAPHY;

EID: 84946087213     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00201.2015     Document Type: Article

References (18)

1. Addison W, Nakano Y, Loisel T, Crine P, McKee M. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite— an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 23: 1638–1649, 2008.
2. Barros NM, Hoac B, Neves RL, Addison WN, Assis DM, Murshed M, Carmona AK, McKee MD. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J Bone Miner Res 28: 688–699, 2013.
3. Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J. Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology (Oxford) 53: 1613–1617, 2014.
4. Cleveland D, Long SE, Sander LC, Davis WC, Murphy KE, Case RJ, Rimmer CA, Francini L, Patri AK. Chromatographic methods for the quantification of free and chelated gadolinium species in MRI contrast agent formulations. Anal Bioanal Chem 398: 2987–2995, 2010.
5. David V, Martin A, Hedge AM, Rowe PS. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 150: 4012–4023, 2009.
6. David V, Martin AC, Hedge AM, Drezner MK, Rowe PS. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate. Am J Physiol Renal Physiol 300: F783–F791, 2011.
7. Fretellier N, Idee J, Bruneval P, Guerret S, Daubine F, Jestin G, Factor C, Poveda N, Dencausse A, Massicot F, Laprevote O, Mandet C, Bouzian N, Port M, Corot C. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol 165: 1151–1162, 2012.
8. Fretellier N, Idee JM, Dencausse A, Karroum O, Guerret S, Poveda N, Jestin G, Factor C, Raynal I, Zamia P, Port M, Corot C. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 46: 292–300, 2011.
9. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18: 614–617, 2006.
10. Idee JM, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: a critical update. Crit Rev Toxicol 44: 895–913, 2014.
11. Kanal E, Broome DR, Martin DR, Thomsen HS. Response to the FDA’s May 23, 2007, nephrogenic systemic fibrosis update. Radiology 246: 11–14, 2008.
12. Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149: 1757–1772, 2008.
13. Rowe PS. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 22: 61–86, 2012.
14. Rowe PSN, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE. Surface plasmon resonance (SPR) confirms MEPE binds to PHEX via the MEPE-ASARM-motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36: 33–46, 2005.
15. Salmon B, Bardet C, Khaddam M, Naji J, Coyac BR, Baroukh B, Letourneur F, Lesieur J, Decup F, Le Denmat D, Nicoletti A, Poliard A, Rowe PS, Huet E, Vital SO, Linglart A, McKee MD, Chaussain C. MEPE-derived ASARM peptide inhibits odontogenic differentiation of dental pulp stem cells and impairs mineralization in tooth models of X-linked hypophosphatemia. PLoS One 8: e56749, 2013.
16. Zelenchuk L, Hedge A, Rowe PS. SPR4-peptide alters bone metabolism of normal and HYP mice. Bone 72: 23–33, 2015.
17. Zelenchuk LV, Hedge AM, Rowe PS. Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif. Bone 79: 131–142, 2015.
18. Zelenchuk LV, Hedge AM, Rowe PS. PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism. PLoS One 9: e97326, 2014.